Cirrus Pharmaceuticals to Invest in cGMP Manufacturing Suite in US
News Nov 13, 2014
Cirrus Pharmaceuticals has announced that it will be investing in a flexible cGMP suite in its facility in RTP, North Carolina.
Ninad Deshpanday, President of R&D at Kemwell said, “With this investment, we are bringing our customers a new service from our US facility. We will offer our clients cGMP manufacturing services for many dosage forms including inhalation, liquids, topicals and oral solids. Our clients will be able to use this service to go to clinic faster. We have completed the design phase and expect the suite to be ready to service customers by April 2015.”
Today, Kemwell’s R&D division employs over 175 scientists worldwide and provides services ranging from formulation development, analytical development and validation to clinical trial manufacturing.
The team has experience working on early stage development programs for NCEs, ANDAs, 505(b)(2) and product life cycle management projects for various customers across the world, including virtual, small and big pharma.
With the addition of the cGMP suite, Cirrus will be able to extend its offerings in the US from contract development to manufacturing.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE